New Leadership Elected to American Society of Hematology
(WASHINGTON, October 30, 2019) – The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of three new members to its Executive Committee for terms beginning after the 2019 ASH Annual Meeting, December 7-10 in Orlando.
Jane Winter, MD, will serve a one-year term as vice president followed by successive terms as president-elect and president. Alison Loren, MD, MSCE, and Bob Löwenberg, MD, PhD, will each serve four-year terms as councillors.
“Drs. Winter, Loren, and Löwenberg have been longstanding members of ASH and have demonstrated leadership and dedication to various ASH committees and publications throughout their years of service. They have greatly contributed to the development of programs that further ASH’s mission, adding tremendous value for hematologists and their patients around the world,” said ASH President Roy Silverstein, MD, of the Medical College of Wisconsin. “Collectively, the perspectives they will bring to the ASH Executive Committee will position the Society to take creative advantage of opportunities and address the challenges facing the field in the immediate future and years to come.”
Dr. Winter is a professor of medicine at Northwestern University’s Feinberg School of Medicine in Chicago. Her research interests include clinical and biologic markers of prognosis in diffuse large B-cell lymphoma, and clinical trials and translational research with novel agents in Hodgkin and non-Hodgkin lymphoma.
Dr. Winter has served in various leadership roles representing the Society, most recently serving as an ASH councillor and member of ASH’s Executive Committee. She was a member of the Committee on Educational Affairs (CEA) for 10 years, served as the Education Program Co-Chair for the annual meeting, and also became Vice-Chair and then Chair of the CEA.
“Never before have there been so many promising scientific advances and new effective therapies in the field of hematology,” said Dr. Winter. “As hematologists, we must embrace new constituencies, such as those who work in immunotherapy or vascular biology with whom we share our basic mission, learn from others, and always be willing to adapt. I’ve worn many hats throughout my years in the field, and am committed to welcoming all who have an interest in hematology under our tent.”
Dr. Loren is an associate professor of medicine, vice chair for faculty development of the department of medicine, and the director of blood and marrow transplantation at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia and a member of Penn’s Abramson Cancer Center. Her research interests include allogeneic hematopoietic cell transplantation, clinical trials, fertility preservation, and cancer survivorship. She has served as chair of the Committee on Training, which provides career and educational opportunities for hematology trainees and the Research Training Award for Fellows study section. Dr. Loren currently serves as co-chair of the ASH Editor Search Committee.
Dr. Löwenberg is a professor of hematology at Erasmus University Rotterdam in Rotterdam, Netherlands. His research interests include molecular and cellular pathobiology of leukemia, and developmental diagnostics and therapeutics in leukemia. At the end of 2019, Dr. Löwenberg will have completed a seven-year term as editor-in-chief of the Society’s flagship journal, Blood. He has previously served as chair of the International Members Committee, which oversees the international efforts of the Society and the Scientific Committee on Transplantation Biology, which is focused on immunotherapeutic strategies. He was also the founding member of the International Consortium of Acute Leukemia, which is an educational initiative that brings together clinicians and researchers from developing countries to implement a standard of care for acute leukemia.
The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, and Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.
Contact:
Sara Khalaf, American Society of Hematology
[email protected]; 202-552-4925
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission